A new publication concerning terlipressin, a compound related to lypressin, appeared on June 1, 2026. The study, titled "Effect of terlipressin on renal outcomes in patients with liver cirrhosis and ascites: a retrospective multicenter study," was published in Expert Review of Clinical Pharmacology.
The paper is described as a retrospective multicenter study examining renal outcomes in patients with liver cirrhosis and ascites treated with terlipressin. No specific findings, results, or conclusions from the study have been provided in the available event data.
Lypressin remains classified as an unapproved research compound. This publication entry documents the appearance of the study in the scientific literature as of its listed date, without further detail on outcomes or clinical implications.
Readers seeking additional information about lypressin, its classification, and related research context can consult the compound overview.